OncoMatch/Clinical Trials/NCT06122610
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Is NCT06122610 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) and Photon Emission Tomography / CT (PET/CT) for neuroendocrine tumors.
Treatment: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) · Photon Emission Tomography / CT (PET/CT) · 64Cu-Dotatate · 177Lu-Dotatate — The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Biomarker criteria
Required: SSTR overexpression
somatostatin receptor-positive neuroendocrine tumor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin - Madison · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify